First human trial begins for new eczema drug candidate
NCT ID NCT07205081
Summary
This is the first study in humans to test the safety and how the body processes a new drug called ATTO-3712. It will involve healthy adults and people with moderate-to-severe atopic dermatitis (eczema). Researchers will give increasing doses to see how well it's tolerated and how long it stays in the body, comparing it to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.